Scope Fluidics raises 14M polish zloty to commercialize rapid POC MDx system

Scope Fluidics said that it has raised 14 million Polish zloty ($3.6 million) by issuing shares. The Warsaw, Poland-based biotechnology company will direct the funds to further development and commercialization of its PCR One molecular diagnostics system as well as its BacterOmic phenotypic antibiotic susceptibility testing system.

The Scope Fluidics PCR One system can detect 20 targets from a raw sample in 15 minutes using rapid thermal cycling, as previously reported. The BacterOmic system, meanwhile, uses 640 independent culturing zones within a microfluidic cartridge to determine minimum inhibitory concentrations for antibiotics.

Scope Fluidics will allocate most of the newly raised funds to increase the market potential of the PCR One system, according to a statement.

The firm said commercialization will include preparation for introducing the system in the US, expansion of the portfolio of diagnostic panels, improvement of intellectual property protection, and conducting research using the system in clinical centers. Scope expects to be ready to commercialize the PCR One system in mid-2020.

The firm also announced that the development of its BacterOmic system has accelerated faster than originally anticipated, with planned European Union certification in mid-2021. The remaining resources from the share issue will go toward generating proof-of-concept for a new, undisclosed project, the firm said.